Table 2.

Longitudinal associations of ALSFRS-R total score and plasma creatinine levels with mortality during follow-up

	No. of patients (%)	ALSFRS-R total score			Plasma creatinine
		HR	95% CI	p Value*	HR	95% CI	p Value*
Overall	1241 (100)	0.88	0.86 to 0.90	p<0.001	0.93	0.91 to 0.94	p<0.001
Gender				p=0.09			p=0.005
Male	793 (64)	0.88	0.86 to 0.91		0.93	0.91 to 0.95
Female	448 (36)		0.84 to 0.89		0.90	0.88 to 0.93
Site of onset				p=0.21			p=0.93
Bulbar	290 (23)	0.87	0.84 to 0.89		0.93	0.91 to 0.94
Other	951 (77)	0.88	0.86 to 0.91		0.93	0.91 to 0.94

*p Values are based on the likelihood ratio test (shared parameter models), adjusted for age, gender, baseline level plasma creatinine, baseline vital capacity and ΔFRS. Participants were followed for a maximum of 31.9 months (median 14.0 months).

ALSFRS-R, amyotrophic lateral sclerosis functional rating scale–revised.